modelInositol
Extends from Pharmacolibrary.Drugs.ATC.A.A11HA07.
Information
| name: | Inositol | |
| ATC code: | A11HA07 | route: | oral |
| compartments: | 1 | |
| dosage: | 2000 | mg |
| volume of distribution: | 0.6 | L |
| clearance: | 10 | L/h |
| other parameters in model implementation | ||
Inositol is a carbocyclic sugar, classified as a vitamin-like compound, and is involved in cellular signaling as a component of phospholipids in cell membranes. It is used as a dietary supplement and has been investigated for use in various conditions including polycystic ovary syndrome (PCOS), psychiatric disorders, and as a supportive agent in metabolic syndrome. Inositol is not classified as an essential nutrient or a registered pharmaceutical, but is widely available as an over-the-counter supplement.
Pharmacokinetics
Estimated PK parameters for healthy adults after oral administration as direct clinical PK data are limited. No published peer-reviewed pharmacokinetic studies in humans providing comprehensive compartmental parameters could be identified.
References
Kaku, K (2014). Efficacy of voglibose in type 2 diabetes. Expert opinion on pharmacotherapy 15(8) 1181–1190. DOI:10.1517/14656566.2014.918956 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24798092
Kim, HS, et al., & Shin, JG (2018). Pharmacodynamic effects of voglibose administered alone, administered with metformin, and administered with metformin in a fixed-dose combination in healthy Korean subjects . International journal of clinical pharmacology and therapeutics 56(11) 544–550. DOI:10.5414/CP203146 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30178742
Ek, B, & Nahorski, S (1988). Muscarinic receptor coupling to inositol phospholipid metabolism in guinea-pig cerebral cortex, parotid gland and ileal smooth muscle. Biochemical pharmacology 37(23) 4461–4467. DOI:10.1016/0006-2952(88)90661-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/2849446
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)